SomaLogic, Inc.
SomaLogic, Inc. (SLGC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
slgc · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Healthcare Information Services · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
SomaLogic, Inc.You SLGC | $396M | N/A | — | — |
 Checkpoint Therapeutics, Inc. CKPT | $368M | N/A | — | -$1.42 |
 Global Cord Blood Corporation CORBF | $127M | 5.92x | — | $4.12 |
 Claritev Corporation CTEV | $461M | N/A | — | -$17.30 |
 G1 Therapeutics, Inc. GTHX | $378M | N/A | — | -$0.93 |
 Orchard Therapeutics plc ORTX | $380M | N/A | — | -$0.62 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for SomaLogic, Inc. (SLGC) measures how much investors pay for each dollar of the company's trailing earnings. SLGC's current PE ratio of N/A is calculated by dividing its stock price of $2.10 by its TTM earnings per share of —.
Frequently asked questions
SLGC pe ratio · 6 questionsSLGC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.10 and TTM EPS of —. Data sourced from Financial Modeling Prep via SLGC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · SomaLogic, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09